Clinical significance of individual genetic mutations in multivariate analysis*
| . | . | NRM . | Relapse . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Oncogenic variant . | n . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| TP53 | |||||||||
| No | 73 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 22 | 0.66 (0.14-3.00) | .59 | 2.59 (1.41-4.74) | .002 | 2.18 (1.25-3.82) | .006 | 1.99 (1.14-3.49) | .02 |
| JAK2 | |||||||||
| No | 43 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 52 | 0.89 (0.37-2.15) | .79 | 0.93 (0.56-1.56) | .79 | 0.90 (0.57-1.41) | .63 | 0.75 (0.47-1.19) | .22 |
| ASXL1 | |||||||||
| No | 74 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 21 | 1.69 (0.66-4.32) | .27 | 0.94 (0.51-1.74) | .84 | 1.08 (0.62-1.88) | .78 | 1.42 (0.85-2.38) | .18 |
| TET2 | |||||||||
| No | 77 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 18 | 0.80 (0.26-2.43) | .69 | 0.81 (0.41-1.60) | .54 | 0.91 (0.50-1.66) | .77 | 0.63 (0.33-1.19) | .15 |
| SRSF2 | |||||||||
| No | 80 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 15 | 1.13 (0.41-3.16) | .81 | 0.68 (0.32-1.45) | .32 | 0.75 (0.39-1.42) | .37 | 0.95 (0.50-1.79) | .87 |
| DNMT3A | |||||||||
| No | 82 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 13 | 1.31 (0.35-4.93) | .69 | 1.04 (0.48-2.23) | .92 | 0.85 (0.43-1.69) | .65 | 1.22(0.63-2.33) | .56 |
| RUNX1 | |||||||||
| No | 82 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 13 | 0.74 (0.20-2.71) | .64 | 0.65 (0.31-1.39) | .27 | 0.64 (0.32-1.29) | .21 | 0.71 (0.37-1.37) | .31 |
| CALR | |||||||||
| No | 83 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 12 | 0.63 (0.08-4.90) | .66 | 1.49 (0.75-2.98) | .26 | 1.19 (0.60-2.35) | .62 | 1.00 (0.52-1.94) | 1.00 |
| SF3B1 | |||||||||
| No | 85 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 10 | 1.56 (0.50-4.86) | .44 | 0.73 (0.29-1.84) | .50 | 0.92 (0.44-1.93) | .83 | 0.96 (0.46-1.99) | .90 |
| No. of gene mutations* | — | — | 1.02 (0.83-1.24) | .88 | 1.02 (0.85-1.22) | .82 | 1.04 (0.87-1.25) | .64 | |
| . | . | NRM . | Relapse . | PFS . | OS . | ||||
|---|---|---|---|---|---|---|---|---|---|
| Oncogenic variant . | n . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . |
| TP53 | |||||||||
| No | 73 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 22 | 0.66 (0.14-3.00) | .59 | 2.59 (1.41-4.74) | .002 | 2.18 (1.25-3.82) | .006 | 1.99 (1.14-3.49) | .02 |
| JAK2 | |||||||||
| No | 43 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 52 | 0.89 (0.37-2.15) | .79 | 0.93 (0.56-1.56) | .79 | 0.90 (0.57-1.41) | .63 | 0.75 (0.47-1.19) | .22 |
| ASXL1 | |||||||||
| No | 74 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 21 | 1.69 (0.66-4.32) | .27 | 0.94 (0.51-1.74) | .84 | 1.08 (0.62-1.88) | .78 | 1.42 (0.85-2.38) | .18 |
| TET2 | |||||||||
| No | 77 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 18 | 0.80 (0.26-2.43) | .69 | 0.81 (0.41-1.60) | .54 | 0.91 (0.50-1.66) | .77 | 0.63 (0.33-1.19) | .15 |
| SRSF2 | |||||||||
| No | 80 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 15 | 1.13 (0.41-3.16) | .81 | 0.68 (0.32-1.45) | .32 | 0.75 (0.39-1.42) | .37 | 0.95 (0.50-1.79) | .87 |
| DNMT3A | |||||||||
| No | 82 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 13 | 1.31 (0.35-4.93) | .69 | 1.04 (0.48-2.23) | .92 | 0.85 (0.43-1.69) | .65 | 1.22(0.63-2.33) | .56 |
| RUNX1 | |||||||||
| No | 82 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 13 | 0.74 (0.20-2.71) | .64 | 0.65 (0.31-1.39) | .27 | 0.64 (0.32-1.29) | .21 | 0.71 (0.37-1.37) | .31 |
| CALR | |||||||||
| No | 83 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 12 | 0.63 (0.08-4.90) | .66 | 1.49 (0.75-2.98) | .26 | 1.19 (0.60-2.35) | .62 | 1.00 (0.52-1.94) | 1.00 |
| SF3B1 | |||||||||
| No | 85 | 1.00 | 1.00 | 1.00 | 1.00 | ||||
| Yes | 10 | 1.56 (0.50-4.86) | .44 | 0.73 (0.29-1.84) | .50 | 0.92 (0.44-1.93) | .83 | 0.96 (0.46-1.99) | .90 |
| No. of gene mutations* | — | — | 1.02 (0.83-1.24) | .88 | 1.02 (0.85-1.22) | .82 | 1.04 (0.87-1.25) | .64 | |
Each gene present in ≥10 patients was individually tested in multivariate analysis with the factors listed in the Appendix.
Tested as continuous variable.